In this issue:
The IL-1 pathway is hyperactive in HS
Defining “flare”
Pain perception in HS
Depression and anxiety in adults with HS
Increased risk for cutaneous and extra-cutaneous infections in HS
HS an independent risk for all-cause mortality
A strong placebo response is seen in HS clinical trials
Non-pharmacologic approaches for HS
Intralesional triamcinolone for fistulous tracts in HS
Optimal infliximab dose for HS treatment
Please login below to download this issue (PDF)